Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892137060> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2892137060 abstract "OBJECTIVE: Data is lacking about FOLFIRINOX use for advanced pancreatic ductal adeno- carcinoma in emerging countries. The objective of this study was to report outcomes of effi cacy and safety in the setting of a South American institution. METHODS: Patients treated with FOLFIRINOX for metastatic or locally advanced pancreatic cancer at Instituto do Câncer do Estado de Sao Paulo (Brazil), between November 2012 and January 2016 were retrospectively reviewed. Baseline characteristics, safety, response and overall survival were analyzed. RESULTS: Sixty-one patients were enrolled (metastatic disease: 31). Median age was 61 years (range 37-74), and 88.5% had ECOG 0 or 1; 90.2% had T3 or T4 tumors and 36.1% had node-positive disease. FOLFIRINOX was given as the fi rst-line treatment in 88.5% of pa- tients, and was discontinued due to disease progression (55.7%), limiting toxicity (31.1%) or maximum benefi t (13.1%). Median number of cycles was 10 (range 1-32). Dose reductions occurred in 81.9%. Grade 3 or 4 toxicity were found in 60.6% and were mainly hematological (36%), neuropathy (19.6%), fatigue (8.2%) and diarrhea (14.7%). Two patients had febrile neutropenia. Hospitalization during treatment occurred in 31.1% of cases, with three potential treatment-related deaths. Median overall survival was 16.26 in the full cohort; 13.6 in patients with metastatic disease, and 18.7 months in locally advanced disease. The response rate was 39.3% (32.2% in metastatic disease and 43.3% in locally advanced disease). CONCLUSION: Despite the high prevalence of grade 3 or 4 toxicities, FOLFIRINOX showed effi cacy for the treatment of patients with advanced pancreatic adenocarcinoma, and is an excellent treatment option in emerging countries." @default.
- W2892137060 created "2018-09-27" @default.
- W2892137060 creator A5001499723 @default.
- W2892137060 creator A5021717288 @default.
- W2892137060 creator A5046487651 @default.
- W2892137060 creator A5055354449 @default.
- W2892137060 creator A5060460159 @default.
- W2892137060 creator A5066394899 @default.
- W2892137060 creator A5084709253 @default.
- W2892137060 creator A5090196974 @default.
- W2892137060 date "2018-01-01" @default.
- W2892137060 modified "2023-09-27" @default.
- W2892137060 title "FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience" @default.
- W2892137060 doi "https://doi.org/10.26790/bjo20181447a197" @default.
- W2892137060 hasPublicationYear "2018" @default.
- W2892137060 type Work @default.
- W2892137060 sameAs 2892137060 @default.
- W2892137060 citedByCount "2" @default.
- W2892137060 countsByYear W28921370602022 @default.
- W2892137060 countsByYear W28921370602023 @default.
- W2892137060 crossrefType "journal-article" @default.
- W2892137060 hasAuthorship W2892137060A5001499723 @default.
- W2892137060 hasAuthorship W2892137060A5021717288 @default.
- W2892137060 hasAuthorship W2892137060A5046487651 @default.
- W2892137060 hasAuthorship W2892137060A5055354449 @default.
- W2892137060 hasAuthorship W2892137060A5060460159 @default.
- W2892137060 hasAuthorship W2892137060A5066394899 @default.
- W2892137060 hasAuthorship W2892137060A5084709253 @default.
- W2892137060 hasAuthorship W2892137060A5090196974 @default.
- W2892137060 hasBestOaLocation W28921370601 @default.
- W2892137060 hasConcept C121608353 @default.
- W2892137060 hasConcept C126322002 @default.
- W2892137060 hasConcept C141071460 @default.
- W2892137060 hasConcept C143998085 @default.
- W2892137060 hasConcept C2777063308 @default.
- W2892137060 hasConcept C2777148230 @default.
- W2892137060 hasConcept C2778850193 @default.
- W2892137060 hasConcept C2780210213 @default.
- W2892137060 hasConcept C2780962732 @default.
- W2892137060 hasConcept C29730261 @default.
- W2892137060 hasConcept C526805850 @default.
- W2892137060 hasConcept C71924100 @default.
- W2892137060 hasConcept C72563966 @default.
- W2892137060 hasConcept C90924648 @default.
- W2892137060 hasConceptScore W2892137060C121608353 @default.
- W2892137060 hasConceptScore W2892137060C126322002 @default.
- W2892137060 hasConceptScore W2892137060C141071460 @default.
- W2892137060 hasConceptScore W2892137060C143998085 @default.
- W2892137060 hasConceptScore W2892137060C2777063308 @default.
- W2892137060 hasConceptScore W2892137060C2777148230 @default.
- W2892137060 hasConceptScore W2892137060C2778850193 @default.
- W2892137060 hasConceptScore W2892137060C2780210213 @default.
- W2892137060 hasConceptScore W2892137060C2780962732 @default.
- W2892137060 hasConceptScore W2892137060C29730261 @default.
- W2892137060 hasConceptScore W2892137060C526805850 @default.
- W2892137060 hasConceptScore W2892137060C71924100 @default.
- W2892137060 hasConceptScore W2892137060C72563966 @default.
- W2892137060 hasConceptScore W2892137060C90924648 @default.
- W2892137060 hasIssue "47" @default.
- W2892137060 hasLocation W28921370601 @default.
- W2892137060 hasOpenAccess W2892137060 @default.
- W2892137060 hasPrimaryLocation W28921370601 @default.
- W2892137060 hasRelatedWork W2408739491 @default.
- W2892137060 hasRelatedWork W2591322107 @default.
- W2892137060 hasRelatedWork W2599910524 @default.
- W2892137060 hasRelatedWork W2807110377 @default.
- W2892137060 hasRelatedWork W2896815895 @default.
- W2892137060 hasRelatedWork W2910998150 @default.
- W2892137060 hasRelatedWork W2941837211 @default.
- W2892137060 hasRelatedWork W3046481916 @default.
- W2892137060 hasRelatedWork W332524067 @default.
- W2892137060 hasRelatedWork W4229863258 @default.
- W2892137060 hasVolume "14" @default.
- W2892137060 isParatext "false" @default.
- W2892137060 isRetracted "false" @default.
- W2892137060 magId "2892137060" @default.
- W2892137060 workType "article" @default.